A5101737578- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Research Studies
- Cancer Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Autophagy in Disease and Therapy
- Ferroptosis and cancer prognosis
- Immune Cell Function and Interaction
- Brain Metastases and Treatment
- T-cell and B-cell Immunology
- AI in cancer detection
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Immune cells in cancer
- Advances in Cucurbitaceae Research
- RNA Interference and Gene Delivery
- Cell Adhesion Molecules Research
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Cancer Mechanisms and Therapy
- Lipid metabolism and biosynthesis
Renmin Hospital of Wuhan University
2016-2025
Wuhan University
2016-2025
Eighth Affiliated Hospital of Sun Yat-sen University
2024-2025
Sun Yat-sen University
2024-2025
Southern University of Science and Technology
2024
Digital Health Cooperative Research Centre
2022
Digital China Health (China)
2022
Henan Cancer Hospital
2016
Zhengzhou University
2016
Guangzhou University
2013
Hepatocellular carcinoma (HCC) is one of the most common malignancies, which causes serious financial burden worldwide. This study aims to investigate potential mechanisms contributing HCC and identify core biomarkers. The gene expression profile GSE41804 was picked out analyze differentially expressed genes (DEGs). Gene ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) analyses were carried using DAVID. We constructed a protein-protein interaction (PPI) network visualize interactions...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, acquired resistance greatly limits survival benefit EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess efficacy and safety stereotactic body radiotherapy (SBRT) plus these patients.In this prospective, randomized, controlled, phase 2 study, participants were recruited from 4...
We proposed to compare the outcomes of first‐line epidermal growth factor receptor–tyrosine kinase inhibitor ( EGFR ‐ TKI ) alone with plus whole‐brain radiotherapy WBRT for treatment brain metastases BM in patients ‐mutated lung adenocarcinoma. A total 1665 were screened from 2008 2014, and 132 enrolled our study. Among patients, 72 (54.5%) harbored a deletion exon 19, 97 (73.5%) showed multiple intracranial lesions, 67 (50.8%) had asymptomatic . Seventy‐nine (59.8%) treated alone, 53...
Abstract In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma signet ring cell carcinoma or peritoneal metastasis, were enrolled to receive 8 cycles of apatinib, tislelizumab, and chemotherapy every 3 weeks, a maintenance therapy apatinib plus tislelizumab for maximum 1 year. Homogeneous receiving ICIs combined at the same time deemed as control group efficacy. The primary endpoint was...
This study aimed to evaluate the efficacy and safety of camrelizumab plus apatinib with or without stereotactic body radiotherapy (SBRT) as first-line therapy for patients hepatocellular carcinoma (HCC) portal vein tumor thrombus (PVTT).This is a multicenter, open-label, noncomparative, randomized trial that recruited HCC type II/III/IV PVTT, who had not previously received systemic therapy. Patients were randomly assigned (2:1) receive (200 mg, every 3 weeks) (250 day) SBRT [95% planning...
For stage T1b-2N0-1 esophageal cancer, the impact of neoadjuvant therapy plus surgery (NS), alone (SA), and adjuvant (ST) on cancer-specific survival (CSS) overall (OS) is uncertain.
Lymphovascular invasion, specifically lymph-blood vessel invasion (LBVI), is a risk factor for metastases in breast invasive ductal carcinoma (IDC) and routinely screened using hematoxylin-eosin histopathological images. However, routine reports only describe whether LBVI present does not provide other potential prognostic information of LBVI. This study aims to evaluate the clinical significance 685 IDC cases explore added predictive value on lymph node (LNM) via supervised deep learning...
Killer cell immunoglobulin-like receptors (KIRs) are important for regulating the killing of virus-infected or cancer cells natural killer (NK) cells. KIR2DS2 can recognize peptides derived from hepatitis C virus (HCV) global flaviviruses (such as dengue and Zika) presented by HLA-C*0102 to activate NK cells, has shown promising results when used immunotherapy. Here, we present complex structure with at a resolution 2·5Å. Our reveals that bind HLA-A*1101 in two different directions....
Abstract CRISPR/Cas12a‐based combinational screening has shown remarkable potential for identifying genetic interactions. Here, we describe an innovative method with rapid construction of a dual‐CRISPR RNA (crRNA) library using gene splicing through overlap extension PCR (SOE PCR) and the adoption CeCas12a, which previously identified strict PAM recognition low off‐targeting to guarantee fidelity efficiency. The custom‐pooled SOE crRNA array (SOCA) double‐knockout could be conveniently...
<p>Supplementary Figure 1. Study time frame.</p>
<p>Supplementary Figure 1. Study time frame.</p>
<div>Abstract<p>Purpose: This study aimed to evaluate the efficacy and safety of camrelizumab plus apatinib with or without stereotactic body radiotherapy (SBRT) as first-line therapy for hepatocellular carcinoma (HCC) patients portal vein tumor thrombus (PVTT). Patients Methods: is a multicenter, open-label, non-comparative, randomized trial that recruited HCC type II/III/IV PVTT, who had not previously received systemic therapy. were randomly assigned (2:1) receive (200 mg,...
Primary analysis of the open-label, single-arm, phase II RENMIN-215 trial (primary data cutoff date: July 10, 2023) showed promising efficacy and tolerable safety with tislelizumab plus fruquintinib fecal microbiota transplantation (FMT) in patients refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Here, we reported updated survival results a median follow-up 34.0 months (data cut-off May 20, 2024), as well patient-reported outcomes laboratory analysis. Twenty MSS...